Table 1 Main outcomes of the BLISS-52 and BLISS-76 trials
| Â | Belimumab 10 mg/kg (%) | Belimumab 1 mg/kg (%) | Placebo (%) |
|---|---|---|---|
SRI response rate at 52 weeks (BLISS-52) | 58 (P = 0.0006) | 51 (P = 0.0129) | 44 |
SRI response rate at 52 weeks (BLISS-76) | 43.2 (P = 0.017) | 40.6 (P = 0.089) | 33.5 |
SRI response rate at 76 weeks (BLISS-76) | 38.5 (P = 0.13) | 39.1 (P = 0.11) | 32.4 |
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-52) | 19 (P = 0.0526) | 21 (P = 0.025) | 12 |
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-76) | 17.5 (P >0.05) | 19.2 (P >0.05) | 12.7 |